April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Who Are the Costliest Recipients of Eye Care in the United States?
Author Affiliations & Notes
  • J. D. Stein
    Ophthalmology and Visual Sciences, Ophthalmology and Visual Sciences,
    University of Michigan, Ann Arbor, Michigan
  • N. Talwar
    Ophthalmology and Visual Sciences, Ophthalmology and Visual Sciences,
    University of Michigan, Ann Arbor, Michigan
  • B. Nan
    Biostatistics, Center for Health Policy,
    University of Michigan, Ann Arbor, Michigan
  • S. M. Kymes
    Ophthalmology and Visual Sciences, Ophthalmology and Visual Sciences,
    Biostatistics, Center for Health Policy,
    Washington University, St. Louis, Missouri
  • D. C. Musch
    Ophthalmology and Visual Sciences, Ophthalmology and Visual Sciences,
    Epidemiology,
    University of Michigan, Ann Arbor, Michigan
  • Footnotes
    Commercial Relationships  J.D. Stein, None; N. Talwar, None; B. Nan, None; S.M. Kymes, None; D.C. Musch, None.
  • Footnotes
    Support  National Eye Institute K23 Mentored Clinician Scientist Award (1K23EY019511-01); American Glaucoma Society Clinician Scientist Grant, Blue Cross Blue Shield of Michigan Foundation, Research to Prevent
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 5833. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. D. Stein, N. Talwar, B. Nan, S. M. Kymes, D. C. Musch; Who Are the Costliest Recipients of Eye Care in the United States?. Invest. Ophthalmol. Vis. Sci. 2010;51(13):5833.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To identify in a large managed care network the sociodemographic characteristics, ocular conditions and ocular surgical procedures of the costliest eye care recipients.

Methods: : Billing records from 2001-2007 for all beneficiaries continuously enrolled in a managed care network for >1 year were reviewed. Charges for eye-related visits, diagnostic and therapeutic ocular procedures, and ocular medications were aggregated; an average yearly charge was computed for each beneficiary. Beneficiaries were ranked from highest to lowest for annual eye-related charges. Logistic regression was performed to determine the sociodemographic characteristics, ocular conditions, and surgical procedures associated with being in the top 1% for eye-related charges.

Results: : Of 4,004,054 persons in the dataset, the 40,041 beneficiaries in the top 1% for eye-related charges had total eye-related charges of $1.01 billion, accounting for 21% of the overall eye-related charges over the 7-year period. The 200,203 persons in the top 5% for eye-related charges had $2.72 billion, or 57%, of the overall eye-related charges. By comparison, those in the lower 50% for eye-related charges accounted for only 7% ($343 million) of the overall eye-related charges. After adjustment for confounding factors, racial minorities, the least-educated persons, and those with estimated net worth <$25,000 were more likely than others to be in the top 1% for eye-related charges. Persons with proliferative diabetic retinopathy (OR=5.41 [CI=5.07-5.79]) and clinically significant macular edema (OR=2.56 [CI=2.39-2.75]) had substantially higher odds of being in the top 1% while those with nonproliferative diabetic retinopathy (OR=1.25 [CI=1.18-1.32]) had only slightly increased odds, compared with those with no retinopathy. Persons with endophthalmitis (OR=3.24 [CI=2.79-3.76]) and suprachoroidal hemorrhage (OR=2.67 [CI=2.10-3.39]) had significantly increased odds of being in the top 1% for eye-related charges.

Conclusions: : In this large sample, racial minorities and those with less education or wealth are more likely to have the highest annual eye-care charges, as are those with surgical complications or more severe ocular manifestations of diseases. These findings support the allocation of resources to identify and treat patients in underserved communities, and provide evidence that may lead to reducing undue costs associated with eye care.

Keywords: clinical (human) or epidemiologic studies: health care delivery/economics/manpower 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×